Apellis Pharmaceuticals Inc (APLS) — Cash Flow-to-Debt Ratio
Apellis Pharmaceuticals Inc (APLS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of $-60.97 Million could theoretically repay 0% of its total liabilities ($667.61 Million) in one year. See Apellis Pharmaceuticals Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apellis Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Apellis Pharmaceuticals Inc across 13 annual periods. Also explore net asset momentum of Apellis Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Apellis Pharmaceuticals Inc (2013–2025)
Year-by-year debt coverage analysis for Apellis Pharmaceuticals Inc. For market capitalisation and broader financial context, see APLS market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $45.33 Million | $705.11 Million | ▲ +148.0% |
| 2024 | -0.13x | $-87.87 Million | $656.51 Million | ▲ +86.6% |
| 2023 | -1.00x | $-594.74 Million | $594.21 Million | ▼ -15.0% |
| 2022 | -0.87x | $-513.75 Million | $590.35 Million | ▼ -5.6% |
| 2021 | -0.82x | $-563.13 Million | $683.10 Million | ▼ -288.3% |
| 2020 | -0.21x | $-160.49 Million | $756.01 Million | ▲ +64.3% |
| 2019 | -0.59x | $-211.13 Million | $355.02 Million | ▲ +80.7% |
| 2018 | -3.08x | $-131.24 Million | $42.56 Million | ▼ -119.6% |
| 2017 | -1.40x | $-46.60 Million | $33.19 Million | ▲ +80.4% |
| 2016 | -7.15x | $-26.00 Million | $3.64 Million | ▼ -21.3% |
| 2015 | -5.89x | $-18.86 Million | $3.20 Million | ▲ +35.9% |
| 2014 | -9.20x | $-9.95 Million | $1.08 Million | ▼ -80.7% |
| 2013 | -5.09x | $-3.44 Million | $676.96K | — |